Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 11/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13622077 | 0.91 | RYR2 (0.52) | RYR2KDM4EALDH1A1MAPT | |
| SCHEMBL7559963 | 0.86 | RYR2 (0.63) | RYR2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL13622172 | 0.84 | RYR2 (0.53) | RYR2KMT2ANOTUM | |
| SCHEMBL13387456 | 0.79 | RYR2 (0.48) | RYR2KMT2ANOTUM | |
| SCHEMBL7556815 | 0.77 | GAA (0.40) | RYR2KDM4EALDH1A1NPSR1NPC1 | |
| SCHEMBL9636604 | 0.76 | RYR2 (0.54) | RYR2ALDH1A1NOTUM | |
| SCHEMBL2692755 | 0.75 | MAPT (0.49) | KDM4EALDH1A1NPSR1NPC1RAB9A | |
| SCHEMBL17227611 | 0.75 | KMT2A (0.62) | NPSR1KMT2APOLBMAPTHTT | |
| SCHEMBL6867136 | 0.74 | RYR2 (0.76) | RYR2ALDH1A1KMT2APOLBMAPT | |
| SCHEMBL8248175 | 0.73 | RYR2 (0.57) | RYR2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2764867-A1 | Agents for preventing and treating disorders Involving modulation of the RYR receptors | The Trustees of Columbia University in the City of New York (US) | 2014-08-13 | — | — | EP | claimed |
| EP-1218010-A2 | 1,4-BENZOTHIAZEPINES TO TREAT OBESITY RELATED DISORDERS | Knoll GmbH (DE) | 2002-07-03 | — | — | EP | claimed |
| WO-2001000185-A2 | 1,4-DENZOTHIAZEPINES TO TREAT OBESITY RELATED DISORDERS | KNOLL GMBH (DE) | 2001-01-04 | — | — | WO | claimed |
| EP-0667866-B1 | 1,4-BENZOTHIAZEPINES USEFUL AS NEUROLOGICAL AGENTS | KNOLL AG (DE) | 1998-03-11 | — | — | EP | claimed |
| US-5580866-A | Therapeutic 1,4-thiazepines | THE BOOTS COMPANY PLC (GB) | 1996-12-03 | — | — | US | claimed |
| EP-0667866-A1 | 1,4-BENZOTHIAZEPINES USEFUL AS NEUROLOGICAL AGENTS | Knoll AG (DE) | 1995-08-23 | — | — | EP | claimed |
| WO-1994011360-A1 | 1,4-BENZOTHIAZEPINES USEFUL AS NEUROLOGICAL AGENTS | THE BOOTS COMPANY PLC (GB) | 1994-05-26 | — | — | WO | claimed |
| EP-1218010-A2 | 1,4-BENZOTHIAZEPINES TO TREAT OBESITY RELATED DISORDERS | Knoll GmbH (DE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001000185-A2 | 1,4-DENZOTHIAZEPINES TO TREAT OBESITY RELATED DISORDERS | KNOLL GMBH (DE) | 2001-01-04 | — | — | WO | disclosed |
| EP-0667866-B1 | 1,4-BENZOTHIAZEPINES USEFUL AS NEUROLOGICAL AGENTS | KNOLL AG (DE) | 1998-03-11 | — | — | EP | disclosed |
| US-5580866-A | Therapeutic 1,4-thiazepines | THE BOOTS COMPANY PLC (GB) | 1996-12-03 | — | — | US | disclosed |
| EP-0667866-A1 | 1,4-BENZOTHIAZEPINES USEFUL AS NEUROLOGICAL AGENTS | Knoll AG (DE) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994011360-A1 | 1,4-BENZOTHIAZEPINES USEFUL AS NEUROLOGICAL AGENTS | THE BOOTS COMPANY PLC (GB) | 1994-05-26 | — | — | WO | disclosed |